Navigation Links
Quark Pharmaceuticals Presents at Asia TIDES Conference
Date:3/9/2009

Highlights First Systemic siRNA Administered in Humans and Quark's Proprietary siRNA Structures

FREMONT, Calif., March 9 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that James D. Thompson, Ph.D., Vice President, Pharmaceutical Development presented an overview of Quark's novel pipeline of synthetic siRNA compounds at the Asia TIDES Oligonucleotide and Peptide(R) Technology and Product Development Conference, held February 24th, 2009 in Tokyo, Japan.

Dr. Thompson's presentation, entitled "Design and Development Strategies for Clinical Applications of Synthetic siRNAs," highlighted Quark's ongoing clinical studies. His case study on QPI-1002 detailed the first systemic administration of a synthetic siRNA in man, results from IND-enabling efficacy and toxicology studies and the largest cGMP manufacture of synthetic siRNA of its time. QPI-1002, also known as I5NP and AKIi-5, is currently being evaluated in two Phase I/IIa clinical studies for the prevention of acute kidney injury (AKI) and a Phase I/II clinical study for the prophylaxis of delayed graft function (DGF) following renal transplantation.

In addition to the case study of QPI-1002, Dr. Thompson provided an update on QPI-1007, Quark's first proprietary siRNA drug candidate based on its intellectual property covering a host of novel structures. The chemically modified siRNA exhibits optimal activity and stability while attenuating potential off-target effects. The novel structures developed in collaboration with BioSpring GmbH give Quark freedom to operate in the siRNA IP space. QPI-1007 is in advanced IND-enabling preclinical studies for the treatment of non-arteritic anterior ischemic optic neuropathy and has demonstrated proof-of-concept efficacy as a neuroprotective agent in animal models of eye diseases<
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
7. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
10. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
11. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... Research and Markets( ... "Deciphering Global Major Pharmaceutical Companies, New Outsourcing ... It has been publicly recognized that ... a series of challenges in the recent years. ... overcapacities in small molecule product manufacturing; increasingly challenging ...
(Date:7/7/2015)... 2015  PAREXEL International Corporation (NASDAQ: PRXL ) will ... 2015 on Wednesday, August 5 th , 2015 after the ... on PAREXEL,s website at www.PAREXEL.com and on the ... host a conference call and live webcast at 10:00 a.m. ... the results.  To access the webcast, visit PAREXEL,s website at ...
(Date:7/7/2015)...   Bionik Laboratories Corp. (OTCBB: BNKL), ... core focus in robotic exoskeleton technology for users ... today that it has completed an additional sale ... its common stock and warrants for aggregate gross ... placement transaction.  This equity financing is the sixth ...
Breaking Medicine Technology:Deciphering Global Major Pharmaceutical Companies - New Outsourcing Demands and Strategies 2Deciphering Global Major Pharmaceutical Companies - New Outsourcing Demands and Strategies 3PAREXEL International Announces Date Of Fourth Quarter And Fiscal Year 2015 Earnings Release And Conference Call 2Bionik Laboratories Completes US$13.1 Million Private Placement 2Bionik Laboratories Completes US$13.1 Million Private Placement 3
... August 10, 2011 Agendia, a commercial-stage ... St. Gallen International Breast Cancer Conference (2011) Expert Panel,s ... patients by the particular biological subtype of their tumor ... According to the panel, "it is no longer tenable ...
... August 10, 2011 The report " ... Current Trends & Forecasts (2010   -   2015) ... administration, and applications; and studies the major market drivers, restraints, ... in North America (U.S. and Canada), Europe, Asia, Japan, ...
Cached Medicine Technology:International St. Gallen Expert Panel Highlights Importance of Molecular Subtyping in Breast Cancer Treatment 2International St. Gallen Expert Panel Highlights Importance of Molecular Subtyping in Breast Cancer Treatment 3MarketsandMarkets: "Radiopharmaceuticals for Therapy and PET/SPECT Imaging" Market to reach $4,734 Million by 2015 2MarketsandMarkets: "Radiopharmaceuticals for Therapy and PET/SPECT Imaging" Market to reach $4,734 Million by 2015 3
(Date:7/7/2015)... ... ... Quadrino Law Group is pleased to announce the relocation of the firm's ... new facility is a state of the art building, located with easy access to ... and founder, said, "We are pleased to service our clients from such a premier ...
(Date:7/7/2015)... ... July 07, 2015 , ... Catalent, ... development solutions for drugs, biologics and consumer health products, today announced that ... its antibody combination therapy (ACT) technology platform. The platform has the potential ...
(Date:7/7/2015)... R.I. (PRWEB) , ... July 07, 2015 , ... Summer ... the proper precautions, however, so Amica Insurance is sharing some safety tips. , Jean ... sports and gardening: , Leisure activities/sports, , Start slowly. Going ...
(Date:7/7/2015)... ... July 07, 2015 , ... On Saturday, May 16th, 2015, the Manistee, ... Golf and Country Club. Best Drug Rehabilitation staff members were delighted to join in ... children. Kiwanis International, the parent of the Manistee Kiwanis Club, is a global organization ...
(Date:7/7/2015)... ... 07, 2015 , ... FSAstore.com today announced the launch of its ... makes it simple to use, spend and manage HSA funds with innovative tools including ... , According to a report by Devenir , approximately 13.8 million Americans have ...
Breaking Medicine News(10 mins):Health News:Catalent Biologics Adds New Technology Platform to Enable Antibody Combination Therapies 2Health News:Amica Insurance Has 7 Summer Safety Tips 2Health News:Best Drug Rehabilitation Team Participates in Kiwanis Club Golf Outing Fundraiser 2Health News:Introducing HSAstore.com: A New E-commerce Site for Health Savings Account Eligible Products and Services 2Health News:Introducing HSAstore.com: A New E-commerce Site for Health Savings Account Eligible Products and Services 3
... 5 ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), ... Development, will participate in a panel discussion on "Adapting Specialty ... Healthcare Conference. The panel will begin at 10:00 a.m. Eastern ... , , To ...
... Closer look at tumors boosts chances for those denied under ... News) -- Many patients with liver cancer who don,t meet ... candidates for liver transplantation, according to an Italian study. , ... single tumor of 5 centimeters or less in diameter, or ...
... reported today that 1 out of 3 American adults do not engage ... the two reasons most cited for these levels of inactivity. , ... ... conducted by the Centers for Disease Control and Prevention (CDC) 2008 Physical ...
... 5 Following a USGS study released today,showing that ... that was tested, the Water Quality Association is encouraging ... According to a report by ... chemicals were not removed by public treatment processes. ...
... PORTLAND, Ore., Dec. 5 Dozens of striking Oak ... rally yesterday on the strike line at Portland,s Oak Harbor Freight ... at Oak Harbor Freight for the past 11 weeks and recently ... , "We believe our retirees have upheld ...
... Fla., Dec. 5 In recognition of the best,Florida ... Blue Foundation for a Healthy Florida, the philanthropic affiliate,of ... announced its 2008,Sapphire Award honorees at a ceremony in ... http://www.newscom.com/cgi-bin/prnh/20050112/NEW019LOGO ) , ...
Cached Medicine News:Health News:New Criteria Could Expand Number of Liver Transplant Candidates 2Health News:Exceeding the Government's Minimum Health Guidelines with a Treadmill Desk 2Health News:Exceeding the Government's Minimum Health Guidelines with a Treadmill Desk 3Health News:Chemicals Remain in Most Treated Water, Says Report 2Health News:Striking Oak Harbor Employees Honor Retirees 2Health News:Florida's Top Health Care Nonprofits Honored With 2008 Sapphire Awards 2
50L...
... Hamilton is precision, ergonomics, and ... hand fatigue with soft non-slip, contoured ... with smooth, light plunger spring action ... and sterilization without the need for ...
... 2000 Pipette is a synonym for pipetting ... robust design, and superior operating comfort. Its ... the measuring stroke and blow-out as well ... system ensures utmost accuracy and precision. Ejection ...
250L...
Medicine Products: